ArticleClinical & translational immunology2021
Interleukin-1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis.
Article in Clinical & translational immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Trans-omics landscape of systemic vasculitis identified matrix metalloproteinase 12 as a novel signature molecule.Rheumatology (Oxford, England) · 2025Article
- Single-cell transcriptome analysis reveals cellular heterogeneity in the aortas of Takayasu arteritis.Arthritis research & therapy · 2025Article
- Prognostic factors associated with acute retinal necrosis treated non-surgically.Eye (London, England) · 2024Article
- Association between premature vascular smooth muscle cells senescence and vascular inflammation in Takayasu's arteritis.Annals of the rheumatic diseases · 2024Article
- Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis.Arthritis research & therapy · 2023Article
- Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors.Frontiers in immunology · 2023Review
- The role of neutrophils in rheumatic disease-associated vascular inflammation.Nature reviews. Rheumatology · 2022Review
- Transcriptome profiling of abdominal aortic tissues reveals alterations in mRNAs of Takayasu arteritis.Frontiers in genetics · 2022Article
- Single-Cell RNA Sequencing Revealed CD14Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLarge vessel vasculitis (LVV) is characterised by a high relapse rate. Because accurate assessment of the LVV disease status can be difficult, an accurate prognostic marker for initial risk stratification is required. We conducted a comprehensive longitudinal investigation of next-generation RNA-sequencing data for patients with LVV to explore useful biomarkers associated with clinical characteristics.
methodsKey molecular pathways relevant to LVV pathogenesis were identified by examining the whole blood RNA from patients with LVV and healthy controls (HCs). The data were examined by pathway analysis and weighted gene correlation network analysis (WGCNA) to identify functional gene sets that were differentially expressed between LVV patients and HCs, and associated with clinical features. We then compared the expression of the selected genes during week 0, week 6, remission and relapse.
resultsThe whole-transcriptome gene expression data for 108 samples obtained from LVV patients (
conclusionUpregulation of the IL-1 signalling pathway was a characteristic of LVV patients and was associated with the extent of disease and a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.